Previous Conferences

Pharma Finance is an international event addressing new technologies for Life Sciences, Biotechnology, Medical Device and newest medical discoveries.

Investment Funds, Pharma and Biotech Companies, as well as multiple Research Centers, participate in the Conference that offer a three-dimensional view of the Italian and worldwide markets and further enhance attending companies’ experience.

There is a dedicated area where presenting companies and scientific groups will show their products meet members of the scientific, business, academic and financial community, in order to evaluate potential collaborations for scientific studies, new partnerships, raise awareness of their pipeline to the attending scientists ,academics and industry management in a comfortable atmosphere.

Previous Editions :


Download Full Catalogue


Pharma Finance 2008

For more information please contact:


Conference Schedule


Presenting Companies



Adventrx Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens.

The Alsium Consortium

The ALSIUM CONSORTIUM is an international initiative gathering public and private research institutions and aimed at setting up innovative technologies and procedures for tissue engineering. To this end, a perfect multidisciplinary organization must be activated promoting the collaboration among biotechnology, material science, bioinformatics, genetic, biology and clinical medicine investigators. This multidisciplinary approach makes Alsium a platform of excellence to promote the most innovative solutions in regenerative medicine.

AMBiotech Srl

AMBiotech S.r.l. was funded in 1999 by research scientists of both governmental and private labs as a spin-off company taking advantage of rich know-how and experiences acquired in the field of plant biotechnologies. Our company operates in the plant biotechnology area, offering both analysis services and technical support. In the last years there is been a rising interest in exploiting plants as biofactories for the production of heterologous proteins of high added value. Indeed plants represent a valid alternative to traditional production systems based on eukaryotic/prokaryotic cell cultures, in terms of product safety/quality and low costs. At present we are involved in research projects in the field of Molecular farming for the large-scale production of Plant-Made Pharmaceuticals (PMPs). (antibodies, vaccines, enzymes, allergens, hormones, antimicrobial peptides etc.)

Competitive Technologies, Inc.

Competitive Technologies, Inc., established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.

Delta  Research & Development

Delta R&D is a bioengineering research centre with a unique history. It was born out of individual research work begun in 1983 by Giuseppe Marineo, a researcher and bioengineer, who advanced theories to reformulate the concept of disease (and the corresponding treatment) from a biophysical rather than biochemical point of view. The idea was to restructure the known features of both according to the principles of thermodynamics by means of an analysis and the detailed specification of the relations between entropy, disease, repair processes and ageing. In May 1998 Delta R&D was set up, thus marking the beginning of the mature stage of this individual research endeavour. Although the original philosophy was retained, a logistical structure was now available to satisfy the new phases of development and to maintain and expand relations with the international scientific community.


InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology, which improves the potency of existing antibody products while opening new markets and disease applications. antibodies utilize unique, novel and patented methods and technologies of InNexus.

Insight Biopharmaceuticals

InSight Biopharmaceuticals Ltd. specializes in the discovery, development, production and commercialization of innovative biopharmaceuticals, diagnostics and biogenerics.

Since 1995 InSight has been a pioneer in introducing high added value biogenerics to important markets and has established strong alliances for technology transfer and product development. InSight offers a diverse line of biogeneric products, active pharmaceutical ingredients and efficient manufacturing technologies.

Innovative product development
As a major part of its portfolio InSight is developing front-edge biopharmaceuticals and novel drugs. The Company maintains strong R&D programs in cancer, inflammation and additional therapeutic areas. InSight has a rich pipeline of small molecule new chemical entities and novel proteins with promising therapeutic potential, covered by extensive and strong IP.

Novel products for clinical use in early cancer diagnosis, staging and prognosis, based on InSight’s strong IP on Heparanase are being developed.

Istituto Superiore di Sanitare

Istituto Superiore di Sanitare: Dept. of Environment and Primary Prevention has recently invented a method to induce or accelerate the proliferation of cells that either are unable to proliferate or have limited replicative potential. The method stems directly from our discovery (J. Cell Biol. 176: 807-818, 2007) that all kinds of non-proliferating cells actively maintain their nonproliferation state by expressing cell cycle inhibitors (CKI). Removal of such inhibitors is sufficient to produce proliferation, even in the absence of growth factors.


LED SpA has a company provided with UNI EN ISO 9001 and UNI EN ISO 13485, whole Quality Certified System that designs and manufactures medical equipment.

Lee's Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is an integrated research-driven and market-oriented pharmaceutical group. Lee aspires to become a successful biopharmaceutical group in Asia providing innovative and high quality pharmaceutical products of value that combat diseases and improve health. Manufacturing and selling activities in China are primarily carried out through Zhaoke, a sino-foreign equity joint venture established in Hefei, Anhui province in 1994. Moreover, the group has obtained license-in drugs and technologies with potential markets from reputable pharmaceutical companies in USA and Europe for both China and Hong Kong markets..

Micro Biological Survey

MBS srl (Limited) is a recent spin-off of Roma Tre University, participated by the Roma Tre University itself, the researchers who set-up the method, an Italian small biotech firm and a France seed-capital company. The business idea is to produce and to commercialize an analytical kit patented by University Roma Tre which utilizes disposable, ready-to-use reaction vials for fast microbiological analyses of food and water samples. The analysis is based on the color change of the vial content that is induced by the presence of bacteria. The analyses can be carried out by untrained personnel and everywhere they are necessary, without the need of any other instrumentation but a thermostat provided on request.

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc., a privately held Delaware Corporation, is developing innovative products for combating cancer. We are creating novel Solutions for Oncology by combining conventional pharmaceutical science (a small molecule approach) with the latest genomic and genetic technologies for drug discovery and development.

QuantRx Biomedical

QuantRx Biomedical is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide. The Company’s technology portfolio, leveraging 15 patents and licenses, includes RapidSenseŽ point-of-care testing products, based on QuantRx core intellectual property related to lateral flow techniques that rapidly provide medical information directly to the healthcare provider or patient. QuantRx affiliate FluoroPharma is developing important molecular imaging agents for positron emission tomography — PET — and fluorescence imaging, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment of disease. Initial application is in the treatment of cardiovascular disease. Other QuantRx technology platforms are genome-based diagnostic chips for the laboratory-based diagnostic market and PAD technology for diagnosis and treatment of women’s health concerns and other medical needs.

Reimbursement Intelligence

Reimbursement Intelligence provides an array of strategic services to get the managed care knowledge and assessment you need to turn high science into highly successful investments. Our team is comprised of a group of senior managers with more than 20 years of expertise in defining reimbursement strategy and business planning. We are uniquely qualified to provide information and services for emerging medical innovations and the bio-capital resources that fund them. Whether you are an investor needing to understand the reimbursement ramifications surrounding the product you are investing in, or an executive who needs to ensure your managed market success, we can help. Investing in or managing a life science or biotech business is not just about the science, it is also about the business and the impact reimbursement issues can have on commercial success.

Strale Tecnologie e Sistemi Srl

Strale Tecnologie e Sistemi Srl is a company headquartered in Rome. Its mission is the design, planning and supply of value added products and services in the ICT sector. The Company, founded in 2006, became operative in September of the same year. It went through the first start-up phase, the most demanding period for a company, as everybody knows. Presently, the market areas to which the company referes to are: Public and private Health; Local and central public administration; Small and Medium companies; Banks and insurance companies. The Company has obtained the ISO 9001:2000 quality certification for design planning, development, support maintenence, installation of data processing products in IT and Telemedicine sector: IT services supply.

Attending Companies:

Expected Attending Companies

Financial Institutions Expected to Attend:

Atlas Venture BankInvest Group
BioFund Cukierman Investment House
Glenrock Israel IHCV
Life Sciences Partners PharmaVentures
Pitango Venture Capital ValiRx




Rome, Italy – May 10-11, 2007


A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development and is therefore, by invitation only and limited to a select group of companies.


Presenting Companies


ADVENTRX Pharmaceuticals, Inc.

is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance.

Bradmer Pharmaceuticals

Bradmer Pharmaceuticals

is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Dr. Mark C. Rogers

MARK C. ROGERS, M.D., M.B.A (Chairman and Chief Executive Officer):

Prior to joining Bradmer, Dr. Rogers was chairman of the board of directors of Aptamera Inc., a Louisville, Kentucky based oncology company that was acquired by Antisoma plc in February 2005.

C & O Pharmaceutical

C & O Pharmaceutical Technology (Holdings) Limited (C & O)

engages in research, manufacturing, marketing and distribution of C & O branded pharmaceutical products, as well as distribution of third party pharmaceutical products in all the provinces of China. Its manufacturing facilities are located in Nanjing. The company currently has a portfolio included 24 C & O-branded pharmaceutical products. C & O has an extensive distribution network covering approximately 3,000 distributors and over 300,000 clinics, pharmacies and hospitals and across the whole of China.


MS. LEE CHING SZE, SUSANA (Executive Director of C & O Pharmaceutical): Pharma Finance 2007 provides our Company with the platform of exposure to international business and investment opportunities. C & O is one of the leading pharmaceutical companies in China with extensive marketing and distribution network, manufacturing and R&D capabilities. The key objective of attending this conference is to introduce C & O to potential business and investment partners who want to tap into the fast growing market of China.

Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.

Dr. Michael Fonstein

Michael Fonstein, Ph.D. (Chief Executive Officer and President):

Dr. Fonstein has served as Cleveland BioLabs’ Chief Executive Officer and President since their inception in June 2003. He served as Director of the DNA Sequencing Center at the University of Chicago from its creation in 1994 to 1998, when he left to found Integrated Genomics, Inc. located in Chicago, Illinois. He served as CEO and President of Integrated Genomics from 1997 to 2003.


CytRx Corporation

, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx is developing products based on three unique platforms: small molecule chaperone amplification, RNAi technology, and DNA vaccines in a variety of therapeutic indications including ALS, obesity, type 2 diabetes, HIV and cardiovascular disease.

Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc.

, a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for the treatment of psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world’s best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.


NovaDel Pharma Inc.

is a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed treatments. The Company’s proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.

Dr. Jan EgbertsJAN H. EGBERTS, M.D. (President and CEO of NovaDel Pharma):Dr. Egberts joined NovaDel in September 2005 as their Chief Operating Officer. He assumed the position of President and Chief Executive Officer in December 2005. In January 2006, Dr. Egberts was elected to the Board of Directors.

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc.

is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit

Harry S. Palmin

HARRY S. PALMIN (President & CEO of Novelos): I am interested in attending the Rome conference, because one of Novelos key objectives is to out-license NOV-002 in Europe. The resources from such potential partnership(s) would offset, in part, the expense of our overall development. In the US, we plan to obtain a marketing partner for NOV-002 after the pivotal Phase 3 NSCLC trial results are available (mid-2009).



is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. PolyMedix plans to file INDs and start human clinical trials for its first antibiotic drug and its anticoagulant antagonist in 2007.


ViRexx Medical

is an Edmonton, Alberta-based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx’s most advanced clinical programs include drug candidates for the treatment of ovarian cancer, chronic Hepatitis B & C and solid tumors. The lead product from the AIT platform is OvaRex MAb, a therapy for late-stage ovarian cancer. ViRexx has licensed to United Therapeutics Corporation (NASDAQ: UTHR), exclusive rights for development and commercialization of OvaRex MAb and four other monoclonal antibodies worldwide, but ViRexx has retained rights to most member nations of the European Union and certain other countries. ViRexx has established strategic relationships with Dompe Farmaceutici, Medison Pharma, Ltd. and Genesis Pharma S.A. for certain European and Middle-East Countries.



, based in Dublin, California, is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase.

Attending Companies

Competitive Technologies

Competitive Technologies

, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.

GeoPharma, Inc.


is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company’s growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma’s competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. Specializes in the development and manufacture of a range of nutritional supplements.



is a privately held development-stage pharmaceutical company dedicated to providing innovative, safe and efficacious treatments for cancer and other life threatening diseases. The combination of OncoVista’s extensive in-house preclinical and clinical expertise with their global drug development network will lead to rapid and cost-effective regulatory approval and commercialization of novel therapies for the treatment of cancer.



Milano, Italy – September 19-20, 2006


A unique two-day intensive approach to ind and to offer in an international environment: AIC, Patents and Licensing, Co-Marketing of Pharmaceuticals and Biotechnology.

Pharma Finance 2006 is not an arena-style conference. It is specifically designed to support in-depth partnership development and is therefore, by invitation only and limited to twelve presenting companies.Biotech and Pharma companies that are engaged in pursuing growth are given the opportunity to develop new contacts and to interact with representatives focusing on emerging and established technologies. The event exposes companies to institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.




Milano, Italy – September 17-18, 2005


Rome, Italy – June 23-24, 2005

This conference is focused on emerging growth nanotech, hightech, biotech, medical and biometric companies from cutting edge backgrounds, including innovative research vehicles and life enhancing pipelines. The event will expose companies to institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities. The conference will include company presentations and one-on-one meetingts with presenting companies.
Milano Group has built extensive European relations with influential partners, which affords our presenters a new audience in the rapidly growing European markets.
We strive to identify small-mid size American technology companies, generally under-exposed/high-value, that offer new, innovative solutions to present to our European partners. Milano Group’s goal is capital infusion, licensing, market expansion and business development. Our European partners are very receptive to our presenters and eager to forge new partnerships. They, like us, realize the potential inherent in innovative American research.
A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Pharmaceuticals and Nutraceuticals.
Pharma Finance 2005 is not an arena-style conference. It is specifically designed to support in-depth partnership development and is therefore, by invitation only and limited to twelve presenting companies.
Biotech and pharmaceutical companies that are engaged in pursuing growth are given the opportunity to develop new contacts and to interact with representatives focusing on emerging adn established technologies. Companies from cutting edge, innovative research vehicles to life-enhancing product pipelines represent and array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. The event will expose companies to institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.
40 % Biotech & BiopharmaA sizable portion of the audience are members of the European biotech industry like NOVARTIS – SIGMA – TAUE – MERK – PROCTOR & GAMBLE – SIENA BIOTEC plus many others. These attendees are looking for potential licensing deals or partnerships with our conference presenters. 20 % Lawfirms & ConsultingSome of the top lawfirms and consulting entities like MANZATO & ASSOCIATI – MORADINI & ASSOCIATI – INTERNATIONAL PHARMACHIM – MEDEPHA plus several others attend our conferences to help our presenters. 40 % Investors & Venture CapitalAs large as the Biotech presence are the European investors like UBS – AFFI – ALBERINI SYZ – ANIMA – OPERA – SCHRODERS – ARCA MERCHANT plus many others. These invited attendees and European partners are looking for American/Foreign investments, especially in undervalued companies.